A Phase 1/2a First-In-Human Study of BMS-986218 (CTL NF) A Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors

Protocol: 
AAAR2426
Phase: 
I/II

A Phase 1/2a First-In-Human Study of BMS-986218 (CTL NF) A Monoclonal Antibody Alone and in Combination with Nivolumab in Advanced Solid Tumors

Are you Eligible? (Inclusion Criteria)

1. Patients with advanced solid tumor
2. Patients must be in good physical shape. This means that patients must be able
to walk, care for themselves, and do light physical activities such as light
housework or office work.
3. This study is for patients age 18 or older

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States